Fluorodeoxyglucose positron-emission tomography-magnetic resonance hybrid imaging: An emerging tool for staging of cancer of the uterine cervix.
Cervical cancer
fluorodeoxyglucose
lymph nodes
positron-emission tomography-magnetic resonance imaging
Journal
World journal of nuclear medicine
ISSN: 1450-1147
Titre abrégé: World J Nucl Med
Pays: Germany
ID NLM: 101286955
Informations de publication
Date de publication:
Historique:
received:
16
04
2020
revised:
04
05
2020
accepted:
06
05
2020
entrez:
29
7
2021
pubmed:
30
7
2021
medline:
30
7
2021
Statut:
epublish
Résumé
Positron-emission tomography-magnetic resonance imaging (PET-MRI) is an emerging hybrid imaging modality that utilizes the superior soft tissue resolution of MR with the metabolic data from PET. In this study, we sought to assess the clinical value of fluorodeoxyglucose (FDG) PET-MRI with dedicated pelvic PET-MR in the initial staging of cervical cancer. In this institutional-approved study, we identified 23 adult females who underwent FDG PET-MRI on hybrid camera for staging of primary uterine cervical cancer that included a dedicated PET-MR of the pelvis. A nuclear medicine physician and a radiologist reviewed the PET, MRI, and fusion-body and pelvis images alone and then with consensus read characterizing PET and MR abnormal findings. There were 23 patients who underwent FDG PET-MRI for initial staging of cervical cancer with an average age of 52.2 ± 14.0 years. A total of 23 suspected lymph nodes in eight different patients were detected within the pelvis with increased metabolic activity on PET. Both the dedicated pelvis and whole-body PET imaging detected the same corresponding pelvic lymph nodes, although the pelvic PET imaging had better lymph node uptake delineation due to longer acquisition time. Using a 10-mm short-axis criterion, MRI identified only 43.5% of the FDG avid lymph nodes. The average SUVmax on the pelvis PET sequences was higher with SUV 8.9 ± 5.2 compared to the whole-body PET with SUV 7.8 ± 5.4 but was not statistically significant (
Identifiants
pubmed: 34321967
doi: 10.4103/wjnm.WJNM_53_20
pii: WJNM-20-150
pmc: PMC8285997
doi:
Types de publication
Journal Article
Langues
eng
Pagination
150-155Informations de copyright
Copyright: © 2020 World Journal of Nuclear Medicine.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Br J Radiol. 2015 Aug;88(1052):20150063
pubmed: 26023947
J Gynecol Oncol. 2016 Jul;27(4):e43
pubmed: 27171673
J Clin Pathol. 2002 Apr;55(4):244-65
pubmed: 11919208
World J Radiol. 2016 Apr 28;8(4):342-54
pubmed: 27158421
Insights Imaging. 2017 Oct;8(5):471-481
pubmed: 28828723
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):67-76
pubmed: 28840302
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):56-65
pubmed: 25223420
EJNMMI Res. 2017 Sep 19;7(1):77
pubmed: 28929350
AJR Am J Roentgenol. 2006 Nov;187(5):W538-43
pubmed: 17056887
AJR Am J Roentgenol. 2018 Oct;211(4):896-900
pubmed: 30106609
Cancer. 2017 Jul 1;123(13):2404-2412
pubmed: 28464289
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Obstet Gynecol. 2016 Mar;127(3):459-467
pubmed: 26855089
Gynecol Obstet Invest. 2017;82(3):209-222
pubmed: 28183074
Clin Imaging. 2014 Jul-Aug;38(4):464-469
pubmed: 24642250
AJR Am J Roentgenol. 2013 Aug;201(2):W192-205
pubmed: 23883234
Cancer Imaging. 2012 Mar 05;12:49-65
pubmed: 22391444
Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):622-629
pubmed: 29164299